CD9 and neoplasm: Along those lines, and as we reported in cell lines in a previous study, our results also revealed that expression of constitutive sEV markers, including tetraspanins CD9, CD63 and CD81, could differ between patient and control samples and, consequently, provide further indication about a specific tumour subtype or progression [24,77,78].